Skip NavigationSkip to Content
Return Return to Search Results

Relationship of Serum Progesterone and Progesterone Metabolites with Mammographic Breast Density and Terminal Ductal Lobular Unit Involution among Women Undergoing Diagnostic Breast Biopsy

  1. Author:
    Hada, Manila
    Oh, Hannah [ORCID]
    Fan, Shaoqi
    Falk, Roni T [ORCID]
    Geller, Berta
    Vacek, Pamela
    Weaver, Donald
    Shepherd, John [ORCID]
    Wang, Jeff
    Fan, Bo
    Herschorn, Sally
    Brinton, Louise A
    Xu,Xia
    Sherman, Mark E
    Trabert, Britton
    Gierach, Gretchen L [ORCID]

  2. Author Address

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Division of Health Policy and Management, College of Health Science, Korea University, Seoul 02841, Korea., Department of Family Medicine, University of Vermont and Vermont Cancer Center, Burlington, VT 05401, USA., Department of Medical Biostatistics, University of Vermont and Vermont Cancer Center, Burlington, VT 05401, USA., Department of Pathology, University of Vermont and Vermont Cancer Center, Burlington, VT 05401, USA., Population Sciences in the Pacific Program (Cancer Epidemiology), University of Hawaii Cancer Center, Honolulu, HI 96813, USA., Graduate School of Medicine, Hokkaido University, Sapporo 060-080, Japan., Department of Radiology & Biomedical Imaging, University of California, San Francisco, CA 94115, USA., Department of Radiology, University of Vermont and Vermont Cancer Center, Burlington, VT 05401, USA., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA., Mayo Clinic, Jacksonville, FL 32224, USA.,
    1. Year: 2020
    2. Date: Jan 17
    3. Epub Date: 2020 01 17
  2. Journal: Journal of clinical medicine
    1. 9
    2. 1
  4. Type of Article: Article
  5. Article Number: 245
  6. ISSN: 2077-0383
  1. Abstract:

    The association of progesterone/progesterone metabolites with elevated mammographic breast density (MBD) and delayed age-related terminal duct lobular unit (TDLU) involution, strong breast cancer risk factors, has received limited attention. Using a reliable liquid chromatography-tandem mass-spectrometry assay, we quantified serum progesterone/progesterone metabolites and explored cross-sectional relationships with MBD and TDLU involution among women, ages 40-65, undergoing diagnostic breast biopsy. Quantitative MBD measures were estimated in pre-biopsy digital mammograms. TDLU involution was quantified in diagnostic biopsies. Adjusted partial correlations and trends across MBD/TDLU categories were calculated. Pregnenolone was positively associated with percent MBD-area (MBD-A, rho: 0.30; p-trend = 0.01) among premenopausal luteal phase women. Progesterone tended to be positively associated with percent MBD-A among luteal phase (rho: 0.26; p-trend = 0.07) and postmenopausal (rho: 0.17; p-trend = 0.04) women. Consistent with experimental data, implicating an elevated 5a-pregnanes/3a-dihydroprogesterone (5aP/3aHP) metabolite ratio in breast cancer, higher 5aP/3aHP was associated with elevated percent MBD-A among luteal phase (rho: 0.29; p-trend = 0.08), but not postmenopausal women. This exploratory analysis provided some evidence that endogenous progesterone and progesterone metabolites might be correlated with MBD, a strong breast cancer risk factor, in both pre- and postmenopausal women undergoing breast biopsy. Additional studies are needed to understand the role of progesterone/progesterone metabolites in breast tissue composition and breast cancer risk.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.3390/jcm9010245
  3. PMID: 31963437
  4. View record in Web of Science®
  5. WOS: 000515388400245
  6. PII : jcm9010245

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel